- Home
- SMTK vs MTEM Comparison
SMTK vs MTEM Comparison
Compare SMTK & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- MTEM
- Stock Information
- Founded
- SMTK 2009
- MTEM 2001
- Country
- SMTK United Kingdom
- MTEM United States
- Employees
- SMTK N/A
- MTEM N/A
- Industry
- SMTK
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMTK
- MTEM Health Care
- Exchange
- SMTK NYSE
- MTEM Nasdaq
- Market Cap
- SMTK 9.5M
- MTEM 9.7M
- IPO Year
- SMTK N/A
- MTEM N/A
- Fundamental
- Price
- SMTK $2.45
- MTEM $0.44
- Analyst Decision
- SMTK
- MTEM
- Analyst Count
- SMTK 0
- MTEM 0
- Target Price
- SMTK N/A
- MTEM N/A
- AVG Volume (30 Days)
- SMTK 17.0K
- MTEM 17.1M
- Earning Date
- SMTK 11-12-2024
- MTEM 11-19-2024
- Dividend Yield
- SMTK N/A
- MTEM N/A
- EPS Growth
- SMTK N/A
- MTEM N/A
- EPS
- SMTK N/A
- MTEM N/A
- Revenue
- SMTK $40,000.00
- MTEM $25,470,000.00
- Revenue This Year
- SMTK N/A
- MTEM N/A
- Revenue Next Year
- SMTK N/A
- MTEM N/A
- P/E Ratio
- SMTK N/A
- MTEM N/A
- Revenue Growth
- SMTK 471.43
- MTEM N/A
- 52 Week Low
- SMTK $2.10
- MTEM $0.30
- 52 Week High
- SMTK $13.00
- MTEM $5.37
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- MTEM 44.19
- Support Level
- SMTK N/A
- MTEM $0.32
- Resistance Level
- SMTK N/A
- MTEM $1.13
- Average True Range (ATR)
- SMTK 0.00
- MTEM 0.09
- MACD
- SMTK 0.00
- MTEM 0.04
- Stochastic Oscillator
- SMTK 0.00
- MTEM 22.72
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.